raised ALT and use of oral hypoglycaemic medication
Last reviewed 03/2018
- hepatic impairment is a contraindication to many different medications.
Of note in diabetes, is the use of glitazones in the case of hepatic impairment
associated with non-alcoholic fatty liver disease
- the first glitazone, thioglitazone, was withdrawn from use after deaths occurred secondary to hepatic failure. However now there is evidence that glitazones are an effective treatment in non-alcoholic fatty liver disease
- the use of glitazone therapy in patients with abnormal liver function tests should only be used on specialist advice (1)
- Personal Communication (February 9th 2006). Aresh Anwar, Consultant Diabetologist, University Hospitals Coventry and Warwickshire.